Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

7 of 9 arms with a reported figure. Choose arms to narrow the chart.

months 6

Vorasidenib 40 mg. median PFS, vorasidenib: 27.7 months, NEJM 2023

Vorasidenib 40 mg. median PFS, placebo: 11.1 months, NEJM 2023

Vorasidenib 40 mg. median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminary

Vorasidenib Phase 1 doses. median PFS: 36.8 months, Phase 1

Ivosidenib Phase 1 doses. median PFS: 13.6 months, 95% CI 9.2 to 33.2

Olaparib 300 mg. median PFS: 2.05 months

Bars in this group share the unit months. 44.1 months is the longest reported value here. A different unit is not redrawn onto this scale.

% 3

Safusidenib (AB-218, DS-1001) 250 mg. 36-month PFS rate: 79.1%, median follow-up 38.8 months

IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in source. 3-year PFS rate: 63%

Olaparib 300 mg. 6-month PFS rate: 31.4%, primary endpoint, target 50% not met

Bars in this group share the unit %. 79.1 % is the longest reported value here. A different unit is not redrawn onto this scale.

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.